Pharmaceutical Composition for Safe and Effective Treatment of Knee and/or Hip Pain

Abstract

A pharmaceutical composition and a method for treating knee and / or hip pain in a patient non-responsive or intolerant to standard analgesic therapy are disclosed. A pharmaceutical composition and a method for reducing risk for developing an arthropathy in a subject receiving an anti-NGF antibody for treatment of knee and / or hip pain are disclosed. Also provided herein are methods for monitoring safety of a treatment of knee and / or hip pain involving administration of an anti-NGF antibody. In certain aspects, the subject has osteoarthritis of the knee and / or hip and the anti-NGF antibody is fasinumab.

Description

FIELD OF THE INVENTION[0001]The present invention relates to the treatment, or prevention of pain in joints such as the knee joint or the hip joint in patients who have a history of inadequate pain relief, or intolerance to standard analgesic therapy. More specifically, the invention relates to the administration of NGF antagonists, in particular a nerve growth factor (NGF) antibody, to reduce knee and / or hip pain in a patient in need thereof.BACKGROUND[0002]Many patients with acute and chronic pain do not receive adequate pain relief despite the wide variety of analgesic medications that are currently available, either because the medications are not effective in all patients, or because their use is limited by toxicity or intolerability. The limitations of currently available analgesic therapies include adverse central nervous system effects, nausea and vomiting, constipation, gastrointestinal bleeding and ulceration, cardiovascular events, renal toxicity, and potential for abuse....

AI Technical Summary

Benefits of technology

Fasinumab effectively reduces knee and hip pain in patients unresponsive or intolerant to standard analgesic therapy, improving pain-associated parameters and reducing the risk of arthropathy, while offering a safer alternative to traditional pain management options.

Problems solved by technology

Many patients with acute and chronic pain do not receive adequate pain relief despite the wide variety of analgesic medications that are currently available, either because the medications are not effective in all patients, or because their use is limited by toxicity or intolerability.

The limitations of currently available analgesic therapies include adverse central nervous system effects, nausea and vomiting, constipation, gastrointestinal bleeding and ulceration, cardiovascular events, renal toxicity, and potential for abuse.

Inadequate pain relief has a profound impact on the quality of life for millions of people worldwide with an associated substantial cost to society, including healthcare cost and loss of productivity.

Images